The Filing Desk

Black Diamond Therapeutics

BDTX · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

BDTX · Last close · November 19, 2026
$1.39
Value Black Diamond Therapeutics yourself

Black Diamond Therapeutics reported revenue of $70 million in fiscal 2025. Its operating margin was 17.9%. The diluted share count rose 4.6%.

BLACK DIAMOND THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed March 16, 2026 · 0001701541-26-000009 Updated
Revenue
$70M
 
Operating margin
17.9%
 
Net income
$22M
 
Free cash flow
—
 
Return on equity
22.9%
92.5 pts
Market cap
$80M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Black Diamond Therapeutics does

Black Diamond Therapeutics is a clinical-stage cancer drug developer. It has no approved products. It is working on what it calls MasterKey therapies, drugs meant to block whole families of cancer-driving gene mutations with one molecule, including in tumors in the brain.

Its lead program is silevertinib, an oral drug that targets a protein called EGFR. It is being tested in a Phase 2 clinical trial in patients with EGFR-mutant non-small cell lung cancer. The company plans to begin a randomized Phase 2 trial in newly diagnosed patients with an EGFR-altered brain cancer called glioblastoma in the second quarter of 2026.

The company has not generated any revenue from its product candidates. It found its drug candidates with its own discovery platform, and it has no sales or marketing organization. It competes with other companies developing cancer treatments.

Its biggest risks, as it describes them

  • Trials failing to show that its drugs are safe and work, or being delayed by slow patient enrollment.
  • Not winning the regulatory approvals it needs to sell a drug.
  • No revenue from its product candidates, so it may never be profitable.
  • Running its lead trial at sites outside the U.S., which U.S. regulators may not accept.
  • Competition from others developing cancer drugs, and no sales team of its own.
From Black Diamond Therapeutics's annual report on Form 10-K, filed March 16, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments21012313199129
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio9.1x8.4x6.8x4.9x8.4x
Quick ratio9.1x8.4x6.8x4.9x8.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Black Diamond Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Black Diamond Therapeutics says to expect

  • Cash runwayThe Company believes that its existing cash, cash equivalents and investments, will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the second half of 2028.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 10, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Black Diamond Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''−4.58−10.73−0.83
Accruals ratio−10.0%−5.2%−5.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets——Pass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Black Diamond Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Black Diamond TherapeuticsFY25—17.9%————
Vir BiotechnologyFY25−7.6%−699.2%−578.5%———Compare
Intellia TherapeuticsFY2516.9%−651.7%−585.0%———Compare
Bicycle TherapeuticsFY25105.8%−340.4%−347.2%———Compare
CompugenFY25161.1%43.0%43.0%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue000———070
Revenue growth————————
Gross profit————————
Research and development722489764595134
Operating income−9−29−70−127−93−86−7912
Net income−9−35−67−126−91−82−7022
Diluted EPS (US$)−4.42−16.99−2.05−3.47−2.52−1.88−1.270.39
Diluted shares (millions)22333636445558
Cash flow
Cash from operations−8−25−52−100−85−67−6230
Capital expenditure0003000—
Free cash flow−9−25−52−103−85−67−62—
Dividends paid00000000
Share buybacks00000000
Acquisitions00000000
Stock-based compensation048141210117
Balance sheet at fiscal year end
Cash and short-term investments5215531521012313199129
Debt incl. finance leases————————
Total assets52158330248156159123143
Total liabilities75225241423931
Shareholders' equity−16−4730819611611783112
Margins and ratios
Gross margin————————
Operating margin———————17.9%
Net margin———————31.9%
Free cash flow margin————————
Rule of 40 (growth + FCF margin)————————
Return on capital————————
Return on equity——−51.6%−49.9%−58.5%−70.9%−69.7%22.9%
Return on assets—−33.6%−27.6%−43.5%−45.1%−52.4%−49.5%16.8%
Net debt to EBITDA————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Black Diamond Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Black Diamond Therapeutics.